Jump to section

Artemis Medicare Services (ARTEMISMED.NS) — Investment Thesis

Status: OWNED (181 shares, ₹44,499 invested, 4.4% of portfolio)

Quality Score: 15/25 (Grade C: Low Conviction)

Last Updated: 2026-03-11

Data Source: Screener.in (consolidated)

Quick Summary

One-line thesis: Single-hospital NCR operator at 37x P/E pricing in 33% FCF CAGR — both valuation models show 35–64% overvaluation even in base case, with no meaningful moat vs Medanta/Max/Apollo in the same geography; the VIMHANS expansion is the only catalyst.

Action: HOLD — consider trimming to 2–3%

Level	Price	Trigger
Buy / Add	Do not buy	Grade C; P/B-ROE bull case = ₹279 vs CMP ₹232 — limited upside even in bull; DCF overvalued at all levels
Hold	₹200 – ₹250	Current range (CMP ₹232, entry ₹245 avg, -5%) — thin loss; hold pending VIMHANS clarity
Sell / Exit	At trigger or if trimming	Promoter holding drops below 50%; VIMHANS cancelled/delayed beyond FY27; OPM below 12%; revenue growth below 10%

Why now (Mar 2026): Position at 4.4% is slightly too large for a Grade C stock. Promoter sold 8% in a block deal to FIIs (positive signal — not distress). The stock is near entry price — no loss to exit. Recommend trimming to 2–3% and redirecting to BANCOINDIA or KERNEX.

1. Business Summary

Mid-sized private hospital operator based in Gurgaon, NCR. Single flagship hospital with 541 beds. Serves primarily Delhi-NCR market. Expanding via asset-light MSA (Management Services Agreement) model — to operate 650+ bed VIMHANS hospital in South Delhi (₹500-520 Cr capex, phased by FY29). The thesis is India's healthcare underpenetration + NCR premium demand, but this is a small, single-location hospital vs large-cap peers (Apollo, Max, Fortis).

2. Quality Score

Dimension	Score (1-5)	Notes
MOAT	2	Single hospital in a competitive NCR market. No significant differentiation vs Apollo Spectra, Max, Medanta (also Gurgaon). Location advantage only.
Management	3	Promoter 58.38% — decent. But promoter holding dropped significantly from 68% in Mar 2024 to 58% — a red flag. Needs monitoring.
Financials	3	ROE 13%, ROCE 15% — below healthcare peers (Apollo 23%+). OPM 16% is decent. Debt manageable (D/E 0.35). Profit CAGR 37% (3Y) strong.
Growth Runway	4	India hospital beds per 1000 population = 1.4 (vs WHO target 3.5). NCR premium healthcare demand growing. VIMHANS expansion adds 650 beds (1.2x current).
Valuation	3	P/E 37 and P/B 4.16x — expensive relative to financials. But DCF implies market is pricing in 33% growth, which is high. Both models say overvalued unless ROE improves significantly.
Total	15/25	Grade C: Low Conviction

3. Why This Could Be a Multi-Bagger

Catalyst 1: VIMHANS expansion. Adding 650 beds in South Delhi by FY29 is a 1.2x capacity increase. If successful, doubles revenue potential over 3-5 years.
Catalyst 2: Operating leverage. As bed occupancy improves, fixed costs spread over larger revenue = OPM expansion from 16% → 20%+.
Catalyst 3: NCR premium healthcare. Gurgaon/South Delhi market growing as corporate insurance coverage expands and medical tourism from smaller cities increases.

4. Key Metrics (Consolidated)

Metric	FY22	FY23	FY24	FY25
Revenue (Cr)	555	737	879	937
Net Profit (Cr)	31	38	49	82
OPM %	~14%	~15%	~15%	16%
ROCE %	—	—	15%	15%
ROE %	—	—	—	13%
Debt/Equity	—	—	—	0.35
Promoter %	68%	—	68%	58.38%
P/E	—	—	—	37.1
P/B	—	—	—	4.16

Growth

5Y Sales CAGR: 11%
3Y Sales CAGR: 19%
3Y Profit CAGR: 37%

Quarterly (Cr)

Quarter	Revenue	Net Profit
Sep 2024	241	22
Dec 2024	232	21
Mar 2025	240	23
Jun 2025	255	21
Sep 2025	275	30

5. Valuation

Current Price: ₹232
Market Cap: ₹3,670 Cr
Shares Outstanding: ~15.8 Cr

Model 1: DCF (Discounted Cash Flow)

Base FCF: ₹82 Cr (FY25 net profit) | Discount rate: 12% | Terminal growth: 5%

Scenario	Growth Rates (5yr)	Fair Value	vs ₹232
Bear	10%→4% declining	₹84	-64%
Base	20%→10% declining	₹118	-49%
Bull	30%→15% declining	₹152	-34%

Reverse DCF: Market is pricing in 33% FCF CAGR — aggressive for a single-hospital operator.

Model 2: P/B-ROE (Justified Price-to-Book)

Book Value: ₹55.8 | Cost of Equity: 12%

Scenario	Sustainable ROE	Justified P/B	Fair Value	vs ₹232
Bear	10% (ROE declines)	0.67x	₹37	-84%
Base	15% (holds)	1.75x	₹98	-58%
Bull	20% (improves)	5.00x	₹279	+20%

Implied ROE: At P/B 4.16x, market implies 28% ROE — more than double the current 13%.

The Valuation Problem

Both models agree: ARTEMIS is significantly overvalued at current price unless ROE doubles to 25-28%. For ROE to reach 28%, the company would need Apollo-class margins (~20%+ OPM) + high asset turnover. Currently OPM is 16% and single-hospital scale limits pricing power.

This looks like a "hospital theme" premium being paid for below-average fundamentals.

6. Risks

Risk	Probability	Impact	Mitigation
Promoter stake drop (68% → 58% in 1 year)	Already happened	High	Investigate reason — secondary sale or pledge?
VIMHANS capex execution risk (₹500Cr)	Medium	High	MSA model limits downside vs ownership
Competition from Medanta, Max in Gurgaon	High	Medium	Differentiation through specialties
Single-hospital concentration	Inherent	High	Mitigation = VIMHANS expansion
P/E compression if growth slows	High	High	At 37x P/E, expensive

7. Exit Triggers

[ ] Promoter holding drops below 50%
[ ] Revenue growth falls below 10% for 2 quarters
[ ] VIMHANS project cancelled or significantly delayed
[ ] OPM declines below 12%
[ ] Better hospital with stronger MOAT available at lower valuation

8. Review Schedule

Next quarterly check: Q4 FY26 results (April/May 2026)
Key events to watch:
Reason for promoter stake reduction (8% sold in FY25)
VIMHANS timeline and capex progress
Bed occupancy and ARPOB trends
Q-o-Q revenue growth trajectory

9. Decision History

Date	Action	Price	Quantity	Reasoning
Multiple	BUY	₹245 avg	181	India healthcare growth, NCR premium hospital

10. Position Sizing Note

4.4% at Grade C is borderline too large. Concerns:

Promoter sold ~10% of their holding in FY25 — this needs an explanation
Both valuation models say overvalued by 35-60% even in bull case
No meaningful MOAT vs Apollo/Medanta/Max in same geography
Consider trimming to 2-3% or exiting if promoter explanation is unsatisfactory

11. Research Log

New learnings, commentary, and thesis updates — most recent first.

Full edit history: git log research/ARTEMIS.md

2026-03-11 — Initial thesis + promoter stake investigation

Built 2-model valuation: DCF (very bearish), P/B-ROE (bearish unless ROE doubles to 28%)
Promoter sale decoded: The 8.15% stake was sold in a single quarter (Sep→Dec 2025). Simultaneously, FII holding surged from 0.37% → 12.47%. This is a block deal / secondary sale to institutional investors — not a pledge invocation or distress sale. FIIs buying at scale is a positive signal (they did due diligence).
Revised read: Promoter sold to FIIs at scale — likely a liquidity event, not a loss of conviction. Still monitor for further reductions.
Market pricing in 33% FCF CAGR for a single-hospital operator — seems aggressive
VIMHANS expansion is the key catalyst, but execution risk + ₹500Cr capex is large for this company
Grade C: 15/25. Still low conviction on fundamentals — valuation expensive, MOAT weak
Quality Score: 15/25. MOAT 2, Management 3, Financials 3, Growth 4, Valuation 3.